AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, lesion composition, examiner performing OCT examination, and sequence of examination
Number of subjects: 200
Study 18698359 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg of AMA1‐C1/Alhydrogel+564 microg CPG 7909 (n = 15)
Number of subjects: 75
Study 18698359 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg of AMA1‐C1/Alhydrogel+564 microg CPG 7909 (n = 30)
Number of subjects: 75
Study 18698359 — intervention group
Group type: COMPARATOR
Intervention: 80 microg of AMA1‐C1/Alhydrogel (n = 30)
Number of subjects: 75
Study 18698359 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1‐C1/Alhydrogel+CPG 7909
Number of subjects: 75
Study 17184595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I)
Number of subjects: 50
Study 17184595 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated with statin, Group II)
Number of subjects: 50
Study 14529680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h infusion of paclitaxel
Number of subjects: 12
Study 14529680 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h infusion of paclitaxel
Number of subjects: 12
Study 14529680 — intervention group
Group type: COMPARATOR
Intervention: 24-h infusion of paclitaxel
Number of subjects: 12
Study 14529680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h vs 6-h infusion regimens
Number of subjects: 12
Study 10068382 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra chips
Number of subjects: 3181
Study 10068382 — intervention group
Group type: COMPARATOR
Intervention: Regular chips (control)
Number of subjects: 3181
Study 10068382 — intervention group
Group type: COMPARATOR
Intervention: Olestra chips and Regular chips (control)
Number of subjects: 3181
Study 8555662 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging protocol at the University of Cincinnati Medical Center
Number of subjects: 18
Study 1846934 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 4
Study 1846934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6197766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) at a constant dose of 8 ng kg‐1 min‐1
Number of subjects: 40
Study 6197766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 40
Study 6197766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30550892 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich meal
Number of subjects: 15
Study 30550892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day high PUFA diet
Number of subjects: 15
Study 30550892 — intervention group
Group type: COMPARATOR
Intervention: MUFA-rich meal
Number of subjects: 15
Study 30550892 — intervention group
Group type: COMPARATOR
Intervention: 5-day high MUFA diet
Number of subjects: 15
Study 28952864 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program with Motivational Interviewing
Number of subjects: 114
Study 28952864 — intervention group
Group type: COMPARATOR
Intervention: Otago Exercise Program without Motivational Interviewing
Number of subjects: 114
Study 28952864 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking as part of the exercise program
Number of subjects: 114
Study 26800392 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg/bid) plus citalopram (40 mg/day)
Number of subjects: 64
Study 26800392 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus citalopram (40 mg/day)
Number of subjects: 64
Study 24304365 — intervention group
Group type: EXPERIMENTAL
Intervention: Open AVR
Number of subjects: 52
Study 24304365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical TAVR
Number of subjects: 52
Study 24304365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 52
Study 22426408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin weekly (60 mg/m2 paclitaxel and AUC 2.7 carboplatin)
Number of subjects: 29
Study 22426408 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adjustments due to toxicity
Number of subjects: 29
Study 18781146 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic stratification in smoking cessation trials
Number of subjects: 0
Study 18781146 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically stratified designs
Number of subjects: 0
Study 17614270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg QD
Number of subjects: 403
Study 17614270 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 microg QD
Number of subjects: 403
Study 15655787 — intervention group
Group type: EXPERIMENTAL
Intervention: FP9 boosted by modified virus Ankara (MVA) encoding the malaria epitope‐thrombospondin‐related adhesion protein insert
Number of subjects: 0
Study 15655787 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 used in heterologous prime‐boost immunization regimens with MVA encoding the circumsporozoite protein
Number of subjects: 0
Study 15655787 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (unvaccinated)
Number of subjects: 0
Study 12354426 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (angiography/revascularization between 4 and 48 hours)
Number of subjects: 2220
Study 12354426 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy among CK-negative but troponin-positive patients
Number of subjects: 2220
Study 12354426 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2220
Study 9613535 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg intrathecal sufentanil
Number of subjects: 63
Study 9613535 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg intrathecal sufentanil
Number of subjects: 63
Study 7655109 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% cream applied once a day
Number of subjects: 449
Study 7655109 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% cream applied once a day
Number of subjects: 449
Study 2676121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 24
Study 2676121 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg/day)
Number of subjects: 24
Study 2676121 — intervention group
Group type: COMPARATOR
Intervention: Control exercise stress tests
Number of subjects: 24
Study 826959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 62
Study 826959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 62
Study 826959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31897949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU (50 μg) daily for 12 weeks
Number of subjects: 80
Study 31897949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30303923 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix alone (300 mg twice daily)
Number of subjects: 571
Study 30303923 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate
Number of subjects: 571
Study 30303923 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate
Number of subjects: 571
Study 30303923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 30303923 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix groups
Number of subjects: 571
Study 26975346 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol monthly (Group A)
Number of subjects: 210
Study 26975346 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol bimonthly (Group B)
Number of subjects: 210
Study 26975346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 210
Study 24308540 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (three garlic tablets orally, twice daily for 14 days)
Number of subjects: 63
Study 24308540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three placebo tablets orally, twice daily for 14 days)
Number of subjects: 63
Study 24308540 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 63
Study 24308540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 22137103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) in postmenopausal women after six months
Number of subjects: 35
Study 22137103 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 35
Study 22137103 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 35
Study 19933753 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) 33-50 microg kg(‐1) day(‐1) for 14 days
Number of subjects: 0
Study 20298324 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation groups (SCG) offered to patients in the intervention group
Number of subjects: 223
Study 20298324 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation groups (SCG)
Number of subjects: 223
Study 16928534 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 120 mL autologous blood into the apical chest drain on the fifth postoperative day, with additional doses on days 7 and 9 if necessary
Number of subjects: 20
Study 16928534 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 120 mL autologous blood
Number of subjects: 20
Study 16928534 — intervention group
Group type: COMPARATOR
Intervention: Tube thoracostomy alone (control group)
Number of subjects: 20
Study 12745096 — intervention group
Group type: EXPERIMENTAL
Intervention: STEAMI
Number of subjects: 654
Study 12745096 — intervention group
Group type: COMPARATOR
Intervention: UAP/NSTEAMI
Number of subjects: 654
Study 10960201 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 32
Study 10960201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine/2 microg/mL fentanyl
Number of subjects: 32
Study 8842502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 8842502 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 24
Study 1498533 — intervention group
Group type: EXPERIMENTAL
Intervention: application-impulse stimulation treatment
Number of subjects: 184
Study 1498533 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 184
Study 6474383 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (4 mg)
Number of subjects: 8
Study 6474383 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 31409541 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management (DCM)
Number of subjects: 444
Study 31409541 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 444
Study 29744313 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education provided by trained health workers
Number of subjects: 113
Study 29744313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psycho-education)
Number of subjects: 113
Study 27377519 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopist-controlled wire guidance
Number of subjects: 216
Study 27377519 — intervention group
Group type: COMPARATOR
Intervention: Assistant-controlled wire guidance
Number of subjects: 216
Study 27377519 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sphincterotome (3.9Fr tip)
Number of subjects: 216
Study 27377519 — intervention group
Group type: COMPARATOR
Intervention: Standard sphincterotome (4.4Fr tip)
Number of subjects: 216
Study 24980612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 IU B.I.D for participants 16 years and over; 18 IU B.I.D for participants 13-15 years; increased to 40 IU B.I.D for participants 16 years and over; 32 IU B.I.D for participants 13-15 years)
Number of subjects: 30
Study 24980612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22497201 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmeted male cyclists
Number of subjects: 587
Study 22497201 — intervention group
Group type: COMPARATOR
Intervention: Nonhelmeted male cyclists
Number of subjects: 587
Study 22497201 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmeted female cyclists
Number of subjects: 587
Study 22497201 — intervention group
Group type: COMPARATOR
Intervention: Nonhelmeted female cyclists
Number of subjects: 587
Study 20818864 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-only CPR
Number of subjects: 1276
Study 20818864 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 1276
Study 17350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Noodle soup with lemonade
Number of subjects: 13
Study 17350803 — intervention group
Group type: COMPARATOR
Intervention: Noodle soup without lemonade
Number of subjects: 13
Study 17350803 — intervention group
Group type: COMPARATOR
Intervention: Noodles
Number of subjects: 13
Study 17350803 — intervention group
Group type: COMPARATOR
Intervention: Bread alone
Number of subjects: 13
Study 17350803 — intervention group
Group type: COMPARATOR
Intervention: Bread with chamomile infusion sweetened with panela
Number of subjects: 13
Study 15533703 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-relevant picture stimuli
Number of subjects: 30
Study 15533703 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic startle stimuli
Number of subjects: 30
Study 15533703 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (healthy controls)
Number of subjects: 30
Study 12120849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led sex education sessions delivered by trained Year 12 peer educators.
Number of subjects: 301
Study 10594400 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. or b.d. for 1 month plus 500 mg clarithromycin (b.d.) and 200 mg furazolidone (b.d.) for 1 week
Number of subjects: 40
Study 10594400 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (not specified in the intervention but mentioned in results)
Number of subjects: 40
Study 10594400 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin and furazolidone
Number of subjects: 40
Study 7486869 — intervention group
Group type: EXPERIMENTAL
Intervention: deprenyl + Sinemet
Number of subjects: 101
Study 7486869 — intervention group
Group type: COMPARATOR
Intervention: placebo-deprenyl + Sinemet
Number of subjects: 101
Study 7486869 — intervention group
Group type: EXPERIMENTAL
Intervention: deprenyl + bromocriptine
Number of subjects: 101
Study 7486869 — intervention group
Group type: COMPARATOR
Intervention: placebo-deprenyl + bromocriptine
Number of subjects: 101
Study 2099197 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg twice daily for seven days
Number of subjects: 0
Study 2099197 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple tetracycline 300 mg twice daily for two weeks
Number of subjects: 0
Study 2099197 — intervention group
Group type: COMPARATOR
Intervention: Placebo for metronidazole
Number of subjects: 0
Study 7425389 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (T)
Number of subjects: 20
Study 7425389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (M)
Number of subjects: 20
Study 7425389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metaproterenol (M) and Theophylline (T)
Number of subjects: 20
Study 31914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation with contingency management
Number of subjects: 801
Study 31914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation without contingency management
Number of subjects: 801
Study 31914790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient navigation)
Number of subjects: 801
Study 31914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early linkage to care
Number of subjects: 801
Study 30968336 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐ER 32 mg
Number of subjects: 170
Study 30968336 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 170
Study 30968336 — intervention group
Group type: COMPARATOR
Intervention: TAcs 40 mg
Number of subjects: 170
Study 30968336 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 170
Study 27884686 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 mL lidocaine 1% (100 mg) mixed with polyvinyl alcohol particles (355‐500 μm)
Number of subjects: 60
Study 27884686 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 10 mL lidocaine 1% (100 mg) injected after embolization
Number of subjects: 60
Study 27884686 — intervention group
Group type: COMPARATOR
Intervention: Group C: Control group
Number of subjects: 60
Study 25884195 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive gender-adapted prevention program in schools (6 school hours, includes educational elements about eating disorders, media influences, self-esteem, body perception)
Number of subjects: 1848
Study 25884195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group evaluation of program components
Number of subjects: 1848
Study 24084344 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to polycyclic aromatic hydrocarbons
Number of subjects: 0
Study 24084344 — intervention group
Group type: COMPARATOR
Intervention: Gene polymorphisms (CYP1A1, CYP1B1, EPHX1, GSTM1, GSTT1, GSTP1)
Number of subjects: 0
Study 21820130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 5600 IU/week
Number of subjects: 54
Study 21820130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 11200 IU/week
Number of subjects: 54
Study 21820130 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 54
Study 21820130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 54
Study 21820130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1600 IU/day
Number of subjects: 54
Study 19730391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 or 10 mg/d) + Olmesartan medoxomil (10, 20, or 40 mg/d)
Number of subjects: 0
Study 19730391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Olmesartan combinations
Number of subjects: 0
Study 19730391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19730391 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 0
Study 19730391 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan monotherapy
Number of subjects: 0
Study 17467884 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 185
Study 17467884 — intervention group
Group type: COMPARATOR
Intervention: Standard suturing
Number of subjects: 185
Study 15479842 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 variants with amino acid insertions (TGNS, SQVN, AQQA, SRPE, APP, PTAPPA) near Gag cleavage sites
Number of subjects: 0
Study 15479842 — intervention group
Group type: COMPARATOR
Intervention: Wild-type HIV-1
Number of subjects: 0
Study 15479842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant protease
Number of subjects: 0
Study 11906576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐incubation of the feed with lactase
Number of subjects: 53
Study 11906576 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 53
Study 9142381 — intervention group
Group type: EXPERIMENTAL
Intervention: LUAE + Apl
Number of subjects: 54
Study 8424290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8424290 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anaesthesia (NLA)
Number of subjects: 40
Study 3688150 — intervention group
Group type: EXPERIMENTAL
Intervention: Group occupational therapy
Number of subjects: 0
Study 3688150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29027329 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 6505
Study 29027329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6505
Study 27647662 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D deficiency
Number of subjects: 3181
Study 27647662 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels
Number of subjects: 3181
Study 24076297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day for 5 days (n = 1498)
Number of subjects: 2998
Study 23768702 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20mg bid (RAC group, n=222)
Number of subjects: 426
Study 23768702 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30mg bid (LAC group, n=228)
Number of subjects: 426
Study 23768702 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20mg bid (RAC group)
Number of subjects: 426
Study 23768702 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30mg bid (LAC group)
Number of subjects: 426
Study 23768702 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID users
Number of subjects: 426
Study 23768702 — intervention group
Group type: COMPARATOR
Intervention: Non-NSAID users
Number of subjects: 426
Study 20228710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment for HD
Number of subjects: 19
Study 20228710 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment for HD
Number of subjects: 19
Study 20228710 — intervention group
Group type: EXPERIMENTAL
Intervention: LSS studies
Number of subjects: 19
Study 18635304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips
Number of subjects: 80
Study 18635304 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 80
Study 16639664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of upper lid tarsus curvature in patients with paralytic lagophthalmos
Number of subjects: 97
Study 16639664 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound evaluation of upper lid tarsus curvature in healthy subjects
Number of subjects: 97
Study 16639664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of upper lid tarsus curvature in both groups
Number of subjects: 97